Ki-67 expression stratifies PD-L1-high NSCLC for immune checkpoint inhibitor plus chemotherapy: a real-world biomarker validation
Ki-67 expression may represent a potential predictive biomarker for identifying PD-L1-high NSCLC patients more likely to benefit from chemo-immunotherapy, though its clinical utility requires confirmation in prospective, randomized studies.
Authors
- Haoqiang Wang
- Baiyang Liu (ORCID: https://orcid.org/0000-0003-0892-1827)
- Peng Liu (ORCID: https://orcid.org/0000-0001-8110-209X)
- Bo Xie
- Xianwen Chen (ORCID: https://orcid.org/0009-0008-5903-8368)
- Juan Zhou (ORCID: https://orcid.org/0000-0003-2500-6110)
- Ning Yang (ORCID: https://orcid.org/0000-0003-4742-6271)
Institutions
- Guangzhou University of Chinese Medicine (CN)
- General Hospital of Guangzhou Military Command (CN)
- Southern Medical University (CN)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2025-11-03
- DOI
- https://doi.org/10.1007/s00262-025-04207-9
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00